We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Use of the Hansen Medical System in Patients With Paroxysmal Atrial Fibrillation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01122173
Recruitment Status : Terminated
First Posted : May 13, 2010
Results First Posted : September 11, 2018
Last Update Posted : September 11, 2018
Information provided by (Responsible Party):
Hansen Medical

Brief Summary:
The purpose of this study is to assess the safety and performance of the Hansen Medical Sensei Robotic System and Artisan Catheter when used to robotically manipulate RF ablation catheters for the treatment of paroxysmal atrial fibrillation (irregular heartbeats originating in the upper chambers of the heart).

Condition or disease Intervention/treatment Phase
Paroxysmal Atrial Fibrillation Device: Ablation Not Applicable

Detailed Description:

Subjects who satisfy the inclusion and exclusion criteria will be treated with an RF ablation catheter and Artisan guide catheters controlled by the Sensei X Robotic Catheter System.

Subject will be followed for a period of one year post ablation procedure.

Follow up visit time frames will be conducted at 7-day, 30-day, 90-day, 180-day and 365-day.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 150 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Single Arm Study of the Hansen System for Introducing and Positioning RF Ablation Catheters in Subjects With Paroxysmal Atrial Fibrillation
Study Start Date : July 2013
Actual Primary Completion Date : April 2017
Actual Study Completion Date : April 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Robotic catheter manipulation, Ablation
To evaluate the safety and effectiveness of the family of Artisan guide catheters when used to remotely introduce and position commercially available cardiac RF ablation catheters to treat subjects with paroxysmal atrial fibrillation.
Device: Ablation
Atrial fibrillation ablation procedure
Other Names:
  • Sensei X Robotic Catheter System
  • Artisan Control Catheter
  • RF Ablation Catheters

Primary Outcome Measures :
  1. Safety-Incidence of Major Complications [ Time Frame: within 7 days of the ablation procedure nd the incidence of esophageal injury or pulmonary vein stenosis through 180 days ]
    The primary safety endpoint was defined as the incidence of major complications, including all early onset (within 7 days of the ablation procedure) major complications, and the incidence of esophageal injury or pulmonary vein stenosis through 180 days.

  2. Effectiveness-Freedom From Symptomatic Atrial Fibrillation (AF), Atrial Flutter, and Atrial Tachycardia Episodes [ Time Frame: 91 - 365 days after the inital ablation procedure ]
    The primary effectiveness endpoint is chronic success as demonstrated by the freedom from symptomatic atrial arrhythmia from days 91 to 365.

Secondary Outcome Measures :
  1. Acute Procedural Success [ Time Frame: Day 0 ]
    Acute procedural success is defined as the successful ablation of at least three of four pulmonary veins as shown by pulmonary vein entrance block per vein during the initial ablation procedure. A subject is considered to be an acute procedural failure if acute procedural success cannot be obtained by using the Hansen system and, as a result, manual manipulation is needed to complete the ablation procedure with the ablation catheter.

  2. Chronic Safety-Incidence of Major Complications [ Time Frame: 8 - 365 days post-procedure ]
    Chronic safety is defined as the incidence of Major Complications during the period from 8 - 365 days following the initial ablation procedure (excluding pulmonary vein stenosis and atrio-esophageal fistula from 8 - 180 days, which are included in the primary safety endpoint). The incidence of pulmonary vein stenosis and atrioesophageal fistula is included during the period from 181 - 365 days.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects with paroxysmal atrial fibrillation who have had two or more spontaneously terminating episodes of atrial fibrillation, that last longer than 30 seconds and shorter than 7 days, in the nine months prior to enrollment. At least one episode must be documented with EKG, TTM, Holter monitor, or telemetry.
  2. Failure of at least one Class I - IV anti-arrhythmic drug (AAD) for PAF as evidenced by recurrent symptomatic PAF, or intolerable side effects due to AADs. AADs are defined in Appendix B.
  3. Signed informed consent.
  4. Age 18 years or older
  5. Able and willing to comply with all pre-, post-, and follow-up testing and requirements.

Exclusion Criteria:

  1. Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.
  2. Previous ablation for atrial fibrillation.
  3. Atrial fibrillation episodes that last less than 7 days and are terminated by cardioversion.
  4. Previous valvular cardiac surgery procedure.
  5. Cardiac artery bypass graft procedure within the previous 180 days.
  6. Previous septal defect repair.
  7. Expecting cardiac transplantation or other cardiac surgery within the next 180 days.
  8. Coronary PTCA/stenting within the previous 180 days.
  9. Documented left atrial thrombus on ultrasound imaging (TEE).
  10. Documented history of a thrombo-embolic event within the previous 365 days.
  11. Diagnosed atrial myxoma.
  12. Presence of an implanted ICD.
  13. Presence of permanent pacing leads.
  14. Significant restrictive, constrictive, or chronic obstructive pulmonary disease or any other disease or malfunction of the lungs or respiratory system with chronic symptoms.
  15. Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study.
  16. Women who are pregnant.
  17. Acute illness or active infection at time of index procedure documented by either pain, fever, drainage, positive culture and/or leukocytosis (WBC > 11,000 mm3) for which antibiotics have been or will be prescribed.
  18. Creatinine > 2.5 mg/dl (or > 221 µmol/L).
  19. Unstable angina.
  20. Myocardial infarction within the previous 60 days.
  21. Left ventricular ejection fraction less than 40%
  22. History of blood clotting or bleeding abnormalities.
  23. Contraindication to anticoagulation medications.
  24. Contraindication to computed tomography or magnetic resonance imaging procedures.
  25. Life expectancy less than 1 year.
  26. Enrollment in another investigational study.
  27. Uncontrolled heart failure (NYHA class III or IV heart failure).
  28. Presence of an intramural thrombus, tumor, or other abnormality that precludes catheter introduction or positioning.
  29. Presence of a condition that precludes vascular access.
  30. Left atrial size ≥ 50mm.
  31. INR greater than 3.0 within 24 hours of procedure.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01122173

Layout table for location information
United States, Arizona
Banner Heart Hospital
Mesa, Arizona, United States, 85206
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, New Jersey
Englewood Hospital and Medical Center
Englewood, New Jersey, United States, 07631
Saint Barnabas Heart Center
Livingston, New Jersey, United States, 07039
United States, South Carolina
Greenville Memorial Hospital
Greenville, South Carolina, United States, 29605
United States, Texas
Texas Health Arlington Memorial/Heart Place
Arlington, Texas, United States, 76012
Texas Cardiac Arrhythmia Research Foundation (TCARF)
Austin, Texas, United States, 78705
Houston Methodist Research Institute
Houston, Texas, United States, 77030
United States, Virginia
Univeristy of Virginia
Charlottesville, Virginia, United States, 22908
IKEM, Dept of Cardiology
Prague, Czechia
Gentofte University Hospital
Hellerup, Denmark, 2900
Hospital Universitario Madrid Montepríncipe
Madrid, Spain
United Kingdom
John Radcliff Hospital
Oxford, United Kingdom, OX39DU
Sponsors and Collaborators
Hansen Medical
Layout table for investigator information
Principal Investigator: Joseph Gallinghouse, M.D. Texas Cardiac Arrhythmia Research Foundation
Principal Investigator: Andrea Natale, M.D. Texas Cardiac Arrhythmia Research Foundation
Study Director: Brenda Cayme, RN., BSN Hansen Medical, Inc.
  Study Documents (Full-Text)

Documents provided by Hansen Medical:
Study Protocol  [PDF] December 11, 2014
Statistical Analysis Plan  [PDF] June 24, 2013

Layout table for additonal information
Responsible Party: Hansen Medical
ClinicalTrials.gov Identifier: NCT01122173    
Other Study ID Numbers: HMP010
First Posted: May 13, 2010    Key Record Dates
Results First Posted: September 11, 2018
Last Update Posted: September 11, 2018
Last Verified: August 2018
Keywords provided by Hansen Medical:
Atrial Fibrillation
Robotic Control
Remote Control
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes